{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:05:36Z","timestamp":1775570736393,"version":"3.50.1"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rhabdomyolysis is a clinical acute syndrome characterized by acute injury or necrosis of skeletal muscle cells and may be life-threatening. We report a rare case of rhabdomyolysis caused by sorafenib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case<\/jats:title>\n                    <jats:p>This case report presents a 31-year-old female patient who experienced rhabdomyolysis during sorafenib treatment following allogeneic hematopoietic stem cell transplantation. The patient underwent the transplantation due to acute myeloid leukemia (AML) and subsequently received sorafenib as maintenance therapy to prevent leukemia relapse. During treatment, she developed bilateral lower limb weakness, a significant increase in creatine kinase (CK) levels, and hypokalemia. After discontinuing sorafenib and initiating supportive treatments, her CK levels gradually decreased. Neuromuscular biopsy results showed rhabdomyolysis and immune-mediated necrotizing myopathy.The patient was followed up in the outpatient clinic after discharge, and the symptoms of myasthenia in both lower limbs have improved. On the 38th day after discharge, laboratory tests showed that the levels of \u03b1-hydroxybutyrate dehydrogenase, creatine kinase, lactate dehydrogenase, and electrolytes had returned to normal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights that sorafenib may cause rare but severe adverse reactions, such as rhabdomyolysis. Clinicians should be vigilant about these potential adverse effects when using sorafenib and enhance patient monitoring and management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1728530","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:18:20Z","timestamp":1771305500000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Sorafenib-induced rhabdomyolysis in a post-transplant patient with acute myeloid leukemia"],"prefix":"10.3389","volume":"16","author":[{"given":"Liuxian","family":"Ke","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]},{"name":"Department of Pharmacy, Guangdong Province Work Injury Rehabilitation Hospital","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingjuan","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guangdong Province Work Injury Rehabilitation Hospital","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guangdong Province Work Injury Rehabilitation Hospital","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijian","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guangdong Province Work Injury Rehabilitation Hospital","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27625","article-title":"Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am J Hematology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0694-3","article-title":"FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions","volume":"34","author":"Antar","year":"2020","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"B4","article-title":"Profiles of drug substances, excipients, and related methodology","volume-title":"Profiles of Drug Substances, Excipients and Related Methodology","author":"Abdelgalil","year":"2019"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3\u2013 internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e37348","article-title":"Sorafenib safety evaluation: Real-world analysis of adverse events from the FAERS database","volume":"10","author":"Ning","year":"2024","journal-title":"Heliyon"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.amjsurg.2021.11.022","article-title":"Management of rhabdomyolysis: A practice management guideline from the Eastern Association for the Surgery of Trauma","volume":"224","author":"Sawhney","year":"2022","journal-title":"Am J Surgery"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/tsaco-2021-000836","article-title":"Rhabdomyolysis: an american association for the surgery of trauma critical care committee clinical consensus document","volume":"7","author":"Kodadek","year":"2022","journal-title":"Trauma Surg Acute Care Open"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2020.101015","article-title":"Rhabdomyolysis","volume":"66","author":"Cabral","year":"2020","journal-title":"Disease-a-Month"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-013-0381-2","article-title":"A case of rhabdomyolysis related to sorafenib treatment for advanced hepatocellular carcinoma","volume":"6","author":"Tsuji","year":"2013","journal-title":"Clin J Gastroenterology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.17235\/reed.2020.6440\/2019","article-title":"Rhabdomyolysis in a patient under treatment with sorafenib","volume":"112","author":"D\u00edaz Alc\u00e1zar","year":"2020","journal-title":"Rev Espa\u00f1ola Enfermedades Digestivas"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2018.07.001","article-title":"Multitargeted kinase inhibitors imatinib, sorafenib and sunitinib perturb energy metabolism and cause cytotoxicity to cultured C2C12 skeletal muscle derived myotubes","volume":"155","author":"Damaraju","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-013-1033-8","article-title":"Hypokalemia-induced rhabdomyolysis","volume":"9","author":"Grifoni","year":"2013","journal-title":"Internal Emergency Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.929758","article-title":"Hypokalemia-induced rhabdomyolysis caused by adrenal tumor-related primary aldosteronism: A report of 2 cases","volume":"22","author":"Chen","year":"2021","journal-title":"Am J Case Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58030431","article-title":"Hypokalemia in diabetes mellitus setting","volume":"58","author":"Coregliano-Ring","year":"2022","journal-title":"Medicina"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1996.48","article-title":"Rhabdomyolysis and myohemoglobinuric acute renal failure","volume":"49","author":"Zager","year":"1996","journal-title":"Kidney Int"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1728530\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:18:22Z","timestamp":1771305502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1728530\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":17,"alternative-id":["10.3389\/fonc.2026.1728530"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1728530","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"article-number":"1728530"}}